Depression and anxiety with rimonabant

Lancet

Volumn 370, Issue 9600, 2007, Pages 1671-1672

  Mitchell, Philip B ^a   Morris, Margaret J ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANANDAMIDE; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; RIMONABANT;

ANXIETY DISORDER; ARTICLE; CLINICAL TRIAL; DEPRESSION; DISEASE SEVERITY; DRUG EFFECT; DRUG SAFETY; FOOD AND DRUG ADMINISTRATION; HOSPITAL ANXIETY AND DEPRESSION SCALE; HUMAN; OBESITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RECEPTOR BLOCKING; RISK FACTOR; WEIGHT REDUCTION;

EID: 36049006465     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(07)61705-X     Document Type: Note

References (13)

1. Di Marzo V., and Matias I. Endocannabinoid control of food intake and energy balance. Nat Neurosci 8 (2005) 585-589
2. Cooke D., and Bloom S. The obesity pipeline: current strategies in the development of anti-obesity drugs. Nat Rev Drug Disc 5 (2006) 921-931
3. Curioni C., and Andre C. Rimonabant for overweight or obesity. Cochrane Database Syst Rev 4 (2006) CD006162.
4. Padwal R., and Majumdar S. Drug treatments for obesity: orlistat, sibutramine, and rimonabant. Lancet 369 (2007) 71-77
5. Christensen R., Kristensen P., Bartels E., Bliddal H., and Astrup A. Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials. Lancet 370 (2007) 1706-1713
6. Onyike C., Crum R., Lee H., et al. Is obesity associated with major depression? Results from the Third National Health and Nutrition Examination Survey. Am J Epidemiol 158 (2003) 1139-1147
7. Food and Drug Administration Endocrinologic and Metabolic Advisory. June 13, 2007. Briefing Information, NDA 21-888 ZIMULTI (rimonabant)-Sanofi-Aventis (2007). http://www.fda.gov/OHRMS/DOCKETS/AC/07/briefing/2007-4306b1-00-index.htm (assessed Aug 6, 2007).
8. Gobbi G., Bambico F., Mangieri R., et al. Antidepressant-like activity and modulation of brain monoaminergic transmission by blockade of anandamide hydrolysis. Proc Natl Acad Sci USA 102 (2005) 18620-18625
9. Hill M., Ho W., Sinopoli K., et al. Involvement of the endocannabinoid system in the ability of long-term tricyclic antidepressant treatment to suppress stress-induced activation of the hypothalamic-pituitary-adrenal axis. Neuropsychopharmacology 31 (2006) 2591-2599
10. Moreira F., Kaiser N., Monory F., et al. Reduced anxiety-like behaviour induced by genetic and pharmacological inhibition of the endocannabinoid-degrading enzyme fatty acid amide hydrolase (FAAH) is mediated by CB1 receptors. Neuropharmacology (2007). published online July 19. DOI:10.1016/j.neuropharm.2007.07.005
11. Griebel G., Stemmelin J., and Scatton B. Effects of the cannabinoid CB1 receptor antagonist rimonabant in models of emotional reactivity in rodents. Biol Psychiatry 57 (2005) 261-267
12. Lu X.-Y., Kim C., Frazer A., et al. Leptin: a potential novel antidepressant. Proc Natl Acad Sci USA 103 (2006) 1593-1598
13. Vinod K., and Hungund B. Role of the endocannibinoid system in depression and suicide. Trends Pharmacol Sci 27 (2006) 539-545